tetano
Editor, Senior Moderator
J Med Virol
. 2023 Feb 1.
doi: 10.1002/jmv.28540. Online ahead of print.
Limited enhancement of antibody and B-cell responses to prototype booster vaccination following SARS-CoV-2 Delta breakthrough infection
Xun Wang[SUP] 1 [/SUP], Xing He[SUP] 2 [/SUP], Shujun Jiang[SUP] 3 4 [/SUP], Zhangfan Fu[SUP] 5 [/SUP], Shuai Jiang[SUP] 1 [/SUP], Xiaoyu Zhao[SUP] 1 [/SUP], Chaoyue Zhao[SUP] 1 [/SUP], Yaning Li[SUP] 2 [/SUP], Dianfan Li[SUP] 2 [/SUP], Wenhong Zhang[SUP] 5 [/SUP], Jingwen Ai[SUP] 5 [/SUP], Yanliang Zhang[SUP] 3 4 [/SUP], Chenqi Xu[SUP] 2 [/SUP], Pengfei Wang[SUP] 1 [/SUP]
Affiliations
Abstract
COVID-19 vaccines are effective at preventing the ancestral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) symptomatic infection and severe disease. However, many new SARS-CoV-2 variants of concern (VOCs), including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2) and the most recent Omicron (B.1.1.529) variants, continue to evolve with enhanced immune escape capabilities, posing serious challenges to the efficacy of current vaccines. Recent studies showed booster doses can remarkably reduce VOCs escape from neutralizing antibody response and can induce strong T-cell and memory B-cell responses[1-4](#ref-0001). Hybrid immunity resulting from the combinations of SARS-CoV-2 infection and vaccination has also been proved to produce antibodies with increased potency and breadth and elicit robust CD4+ T-cell populations with enhanced antiviral properties[5,6](#ref-0005). But is unclear that how infection and vaccination history affect immune imprinting and whether it's necessary to have a booster vaccination for people who had a breakthrough infection post-vaccination This article is protected by copyright. All rights reserved.
. 2023 Feb 1.
doi: 10.1002/jmv.28540. Online ahead of print.
Limited enhancement of antibody and B-cell responses to prototype booster vaccination following SARS-CoV-2 Delta breakthrough infection
Xun Wang[SUP] 1 [/SUP], Xing He[SUP] 2 [/SUP], Shujun Jiang[SUP] 3 4 [/SUP], Zhangfan Fu[SUP] 5 [/SUP], Shuai Jiang[SUP] 1 [/SUP], Xiaoyu Zhao[SUP] 1 [/SUP], Chaoyue Zhao[SUP] 1 [/SUP], Yaning Li[SUP] 2 [/SUP], Dianfan Li[SUP] 2 [/SUP], Wenhong Zhang[SUP] 5 [/SUP], Jingwen Ai[SUP] 5 [/SUP], Yanliang Zhang[SUP] 3 4 [/SUP], Chenqi Xu[SUP] 2 [/SUP], Pengfei Wang[SUP] 1 [/SUP]
Affiliations
- PMID: 36722359
- DOI: 10.1002/jmv.28540
Abstract
COVID-19 vaccines are effective at preventing the ancestral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) symptomatic infection and severe disease. However, many new SARS-CoV-2 variants of concern (VOCs), including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2) and the most recent Omicron (B.1.1.529) variants, continue to evolve with enhanced immune escape capabilities, posing serious challenges to the efficacy of current vaccines. Recent studies showed booster doses can remarkably reduce VOCs escape from neutralizing antibody response and can induce strong T-cell and memory B-cell responses[1-4](#ref-0001). Hybrid immunity resulting from the combinations of SARS-CoV-2 infection and vaccination has also been proved to produce antibodies with increased potency and breadth and elicit robust CD4+ T-cell populations with enhanced antiviral properties[5,6](#ref-0005). But is unclear that how infection and vaccination history affect immune imprinting and whether it's necessary to have a booster vaccination for people who had a breakthrough infection post-vaccination This article is protected by copyright. All rights reserved.